Global Genomics Group (“G3″) Appoints Harry “Chip” Davis, Zetia® Inventor, As Chief Drug Development Officer

RICHMOND, Va., May 6, 2014 /PRNewswire/ — Global Genomics Group (G3), a life sciences company investigating biological networks that lead to the development of disease to identify novel diagnostic biomarkers and therapeutic targets, today announced the appointment of Harry “Chip” Davis, Jr., Ph.D., as chief drug development officer. Dr. Davis will be leading the drug discovery group together with Szilard Voros, M.D., co-founder and CEO of G3.

Read the full article here: http://www.marketwatch.com/story/global-genomics-group-g3-appoints-harry-chip-davis-zetia-inventor-as-chief-drug-development-officer-2014-05-06

Global Genomics Group (“G3″) Appoints Harry “Chip” Davis, Zetia® Inventor, As Chief Drug Development Officer
News